For instance, OTUD6B, USP7 and COPS5, frequently found overexpressed in breast cancers, have been regarded as promising therapeutic targets.4,5 Nevertheless, the underlying mechanisms of DUBs in promoting NSCLC tumorigenesis remain poorly understood, which has hindered the discovery of DUBs inhibitors for NSCLC treatment. Here, OTUD6B is linked to non-small cell lung carcinoma.